GSF Spółka z Ograniczoną Odpowiedzialnością (KRS 0000856264, NIP 9930677954) is a Polish company, headquartered in Tarnów, Małopolskie voivodeship. GSF operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since August 25, 2020. GSF's most recently reported net revenue was 0 PLN for 2024.
Negative equity
Negative equity in 2 of 4 available reporting years.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - GSF
Identity
- Name
- GSF Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- August 25, 2020
- Registry status as of
- June 30, 2026
- Latest entry
- June 30, 2026
- Founding act
- 21.08.2020 R.
Articles of association history (1)
- August 21, 2020: 21.08.2020 R.
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. PRZEMYSŁOWA, 27A, 33-100, TARNÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- TARNÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - GSF
Credibility rating
29.9 / 100
Poor credibility
Insolvency risk
Very low
Elevated threat
Closure risk
30
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/6 yrs
Board changes
3
3/6 yrs
PKD changes
0
0/6 yrs
Name changes
0
0/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2021–2024
Current: E (30/100)
Trend: deteriorating (-3.0 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2021–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - GSF
Founded
August 25, 2020
5 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
TARNÓW
MAŁOPOLSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.3 K PLN
70 shares total
Shareholders
3
shareholders
Board
2 people
Filed years
4 years
2021–2024 · profitable: 0/4
Registry entries
21
latest: June 30, 2026
Risk signals
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
2.6 K PLN
2024
Equity
-308 PLN
2024
Valuation
1.6 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - GSF.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
